Stock Rating Downgrade
The Value Trend Rating for Astrazeneca PLC (NASDAQ: AZN) weakened of late from B to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
Astrazeneca PLC (NASDAQ: AZN) stock rose slightly by 0.08% on 6/14/24. The stock closed at $79.59. However, exceptionally low trading volume at 41% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months but has declined -1.5% during the last week.
Current PriceTarget Research Rating
AZN is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Astrazeneca has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Astrazeneca has a neutral Power Rating of 50 and a slightly negative Appreciation Score of 37, with the Low Neutral Value Trend Rating the result.
Be the first to comment